Journal Article

A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling

Stein, Harald, Dierlamm, Judith, Stürzenhofecker, Benjamin, Berger, Hilmar, Bernd, Heinz-Wolfram, Trautmann, Heiko, Martin-Subero, Jose Ignacio, Wessendorf, Swen, Hasenclever, Dirk, Rosolowski, Maciej, Harder, Lana, Rosenwald, Andreas, Trümper, Lorenz, Hansmann, Martin-Leo, Möller, Peter, Müller-Hermelink, Hans-Konrad, Szczepanowski, Monika, Feller, Alfred C, Haralambieva, Eugenia, Bentink, Stefan, Barth, Thomas F.E, Siebert, Reiner, Lenze, Dido, Klapper, Wolfram, Ott, German, Kühn, Michael, Hummel, Michael, Spang, Rainer, Cogliatti, Sergio B, Parwaresch, Reza M, Schwaenen, Carsten, Lichter, Peter, Wacker, Hans-Heinrich, Pott, Christiane, Loeffler, Markus

2006

Overview

Analysis of gene-expression patterns led to the development of a molecular definition of Burkitt's lymphoma that distinguishes it from other types of mature aggressive B-cell lymphoma. Almost all cases defined by the gene-expression signature as Burkitt's lymphoma had the typical Burkitt's IG-myc translocation. Patients whose tumors did not have the Burkitt's signature had a poor outcome if the tumor cells had complex chromosomal changes. Analysis of gene-expression patterns led to the development of a molecular definition of Burkitt's lymphoma that distinguishes it from other types of mature aggressive B-cell lymphoma. Patients whose tumors did not have the Burkitt's signature had a poor outcome if the tumor cells had complex chromosomal changes. Burkitt's lymphoma and diffuse large-B-cell lymphoma are mature aggressive B-cell lymphomas. If left untreated, they follow a rapid clinical course and are fatal within months. Burkitt's lymphoma is a distinct entity that includes endemic and sporadic types and cases associated with immunodeficiency or immunosuppression. 1 With the use of chemotherapy regimens that involve methotrexate and cytarabine, cure rates for sporadic Burkitt's lymphoma approach 90 percent in children and 70 percent in adults. 2 Diffuse large-B-cell lymphoma, by contrast, is biologically and clinically heterogeneous and comprises five morphologic variants and three subtypes. 3 Treatment with a combination of chemotherapy based on cyclophosphamide, doxorubicin, vincristine, . . .

• Publisher: Massachusetts Medical Society
• Subject: Algorithms / Biological and medical sciences / Burkitt Lymphoma - diagnosis / Burkitt Lymphoma - genetics / Burkitt Lymphoma - pathology / Chemotherapy / Diagnosis, Differential / DNA, Neoplasm - analysis / Female / Follow-Up Studies / Gene Expression / Gene Expression Profiling / General aspects / Genes, bcl-2 / Genes, Immunoglobulin / Genes, myc / Hematologic and hematopoietic diseases / Humans / Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis / Lymphoma / Lymphoma, B-Cell - classification / Lymphoma, B-Cell - diagnosis / Lymphoma, B-Cell - genetics / Lymphoma, B-Cell - mortality / Male / Medical research / Medical sciences / Middle Aged / Oligonucleotide Array Sequence Analysis / Oncogene Proteins, Fusion - genetics / Prognosis / RNA, Neoplasm - analysis / Survival Rate / Transcription, Genetic / Translocation, Genetic